C.R. Bard, Inc. v. U.S. Surgical Corp.

Decision Date04 August 2000
Docket NumberNo. Civ.A. 99-286-RRM.,Civ.A. 99-286-RRM.
Citation107 F.Supp.2d 489
PartiesC.R. BARD, INC., and Davol Inc., Plaintiffs, v. UNITED STATES SURGICAL CORPORATION, Defendant.
CourtU.S. District Court — District of Delaware

Jack B. Blumenfeld, Maryellen Noreika, Morris, Nichols, Arsht & Tunnell, Wilmington, Delaware, Peter B. Ellis, Claire Laporte, Sarah Cooleybeck, John Nilsson, Foley, Hoag & Eliot, LLP, Boston, MA, for plaintiffs.

Andre G. Bouchard, Joel Friedlander, Bouchard Margules & Friedlander, Wilmington, Delaware, Eric J. Lobenfeld, Drew M. Wintringham, Michael R. Graif, Chadbourne & Parke LLP, New York City, for defendant.

AMENDED OPINION

McKELVIE, District Judge.

This is a patent case. Plaintiff C.R. Bard, Inc. is a New Jersey corporation with its principal place of business in Murray Hill, New Jersey. Bard owns U.S.Patent No. 5,356,432, as reexamined ("the '432 patent"). Plaintiff Davol Inc., a wholly owned subsidiary of Bard, is a Delaware corporation with its principal place of business in Cranston, Rhode Island. Davol markets and sells products that practice the '432 patent. Defendant United States Surgical Corp. is a Delaware corporation with its principal place of business in Norwalk, Connecticut.

On April 10, 2000, U.S. Surgical moved for summary judgment of noninfringement of claim 20 of the '432 patent and no inducement of infringement of claim 21 of the '432 patent.

On June 2, 2000, the court held a trial in accordance with Markman v. Westview Instruments, Inc., 517 U.S. 370, 116 S.Ct. 1384, 134 L.Ed.2d 577 (1996), to construe disputed claims of the '432 patent. On June 15, 2000, the court issued an opinion construing claim 20 and claim 21 of the '432 patent.

On June 22, 2000, the court heard oral argument on U.S. Surgical's motion for summary judgment. Subsequent to the oral argument, both parties submitted supplemental briefing on the motion.

This is the court's decision on U.S. Surgical's motion for summary judgment.

I. FACTUAL AND PROCEDURAL BACKGROUND

The court takes the following facts from the prosecution history of the '432 patent and from the affidavits submitted by the parties.

A. The Parties' Hernia Plugs

Bard manufactures and sells a hernia plug, called the Perfix plug, which it acknowledges is an embodiment of the '432 patent. The plug has a pleated outer surface, and has several interior mesh petals that may be removed by a surgeon to vary the stiffness of the plug.

U.S. Surgical manufactures and sells a hernia plug called the Hernia-Mate. The Hernia-Mate is a pre-formed mesh plug consisting of a semicircle of mesh joined at the seam. The Hernia-Mate has no pre-formed pleats. The Hernia-Mate has petals that impart bulk to the plug.

U.S. Surgical has prepared marketing and instructional materials that explain how to use the Hernia-Mate. A package insert created by U.S. Surgical states that "[i]f the overall bulk of the SURGIPRO HERNIA-MATE is deemed excessive, then some of the inside `petals' may be trimmed." A brochure designed by U.S. Surgical illustrates the plugs, and under the caption "Removable Petals for Bulk Reduction," states that "[p]lug internal bulk is adjustable by petal removal, to conform to expansion or contraction guaranteeing a true tension free repair."

B. Claim Construction

In its claim construction opinion, the court determined that the language of claim 20 referring to the "surface of said hollow plug being conformable" invokes 35 U.S.C. § 112, ¶ 6, and requires pre-formed pleats which render the plug "extremely pliable, allowing localized portions of the hollow plug to adapt to irregularities in the tissue or muscle wall defect."

The court also determined that trimming a portion of the petals recited in claim 21 is not covered by the literal scope of the claim.

C. U.S. Surgical's Motion for Summary Judgment

In its supplemental briefing on its motion for summary judgment, U.S. Surgical contends that the court's claim construction precludes a finding of literal infringement of claim 20 because the Hernia-Mate plug lacks pre-formed pleats. U.S. Surgical argues, moreover, that there is no genuine issue of material fact as to noninfringement under the doctrine of equivalents, because Bard surrendered its claims to an unpleated structure during the prosecution history, and because U.S. Surgical's Hernia-Mate unpleated plug is substantially different from Bard's pleated plug. As to claim 21, U.S. Surgical claims that summary judgment is proper, because Bard has produced no evidence that the instructional materials created by U.S. Surgical actually reach doctors and induce them to detach entire petals of the plug to vary its stiffness and bulk.

Bard argues that U.S. Surgical literally infringes claim 20, because the Hernia-Mate is equivalent to the claimed invention under § 112, ¶ 6. Bard argues, moreover, that genuine issues of fact preclude granting summary judgment as to infringement under the doctrine of equivalents. Bard contends that the instructional materials prepared by U.S. Surgical create a question of fact as to whether U.S. Surgical has induced infringement of claim 21, precluding summary judgment.

II. DISCUSSION
A. Legal Standards for Granting Summary Judgment

The court may grant summary judgment "if the pleadings, depositions, interrogatories, and admissions on file, together with the affidavits, if any, show that there is no genuine issue as to any material fact and that the moving party is entitled to a judgment as a matter of law." Fed. R.Civ.P. 56(c). Summary judgment is appropriate under the doctrine of equivalents where the evidence is such that no reasonable jury could find equivalency. See, e.g., Digital Biometrics, Inc. v. Identix, Inc., 149 F.3d 1335, 1349-50 (Fed.Cir.1998).

B. Claim 20

The Federal Circuit has explained the standard for determining literal infringement under § 112, ¶ 6 as follows:

Under § 112, ¶ 6, an accused device with structure not identical to the structure described in the patent will literally infringe the patent if the device performs the identical function required by the claim with a structure equivalent to that described in the patent. Prosecution history is relevant to the construction of a claim written in means-plus-function form. Indeed, just as prosecution history estoppel may act to estop an equivalence argument under the doctrine of equivalents, positions taken before the PTO may bar an inconsistent position on claim construction under § 112, ¶ 6. Clear assertions made in support of patentability thus may affect the range of equivalents under § 112, ¶ 6. The relevant inquiry is whether a competitor would reasonably believe that the applicant had surrendered the relevant subject matter.

Cybor Corp. v. FAS Technologies, Inc., 138 F.3d 1448, 1457 (Fed.Cir.1998) (en banc) (citations omitted); accord Alpex Computer Corp. v. Nintendo Co. Ltd., 102 F.3d 1214, 1221-22 (Fed.Cir.1996). Under this standard, a patentee may not claim equivalents under § 112, ¶ 6 when a competitor would reasonably believe that the applicant surrendered its claims to the allegedly equivalent structure during the prosecution of the patent.

Prosecution history estoppel limits infringement by otherwise equivalent structures, by barring recapture by the patentee of scope that was surrendered in order to obtain allowance of the claims. Pall Corp. v. Micron Separations, Inc., 66 F.3d 1211, 1218 (Fed.Cir.1995). Prosecution history estoppel normally arises when a change of claim scope is made in order to overcome an examiner's rejection based on prior art. Id. at 1219. Thus, a patentee is estopped from recovering through equivalency that which was deemed unpatentable in view of the prior art. Id.

Because prosecution history estoppel may preclude a finding of infringement of the '432 patent by statutory equivalence under § 112, ¶ 6, and by the doctrine of equivalence, the court will consider the parties' positions as to whether Bard surrendered claims to an unpleated structure during the prosecution history.

U.S. Surgical asserts that Bard made numerous statements during the prosecution of the '432 patent that serve to limit the scope of its coverage to a pleated structure. U.S. Surgical notes that the examiner rejected claim 20 during the reexamination proceedings in light of a prior art publication by Ermanno Trabucco, which disclosed a hernia plug made by suturing a square piece mesh into a conical, four-lobed configuration. U.S. Surgical contends that Bard attempted to overcome this reference by stating: "[I]t is the integrally formed pleats, and not additional fastening mechanisms (such as the sutures or clips disclosed by Trabucco), which allow the prosthesis to conform to the contours of the defect merely upon placement in the tissue or muscle wall opening." U.S. Surgical also notes that, after the examiner proposed amending claim 20 to insert means-plus-function language into claim 20, Bard stated: "In accordance with the Examiner's suggestion, claims 19 and 20 have been amended to clearly distinguish the arrangement shown in the Trabucco article." U.S. Surgical contends that it was reasonable for it to rely on this statement as limiting the scope of claim 20 to a pleated structure. U.S. Surgical asserts that this court's determination that claim 20 is written in means-plus-function language demonstrates that it was reasonable to rely on Bard's statement as an indication that Bard surrendered its claims to an unpleated structure.

Bard argues that it is not estopped from claiming equivalents of a disclosed structure unless it unequivocally and unmistakably surrendered the equivalent structures. See Athletic Alternatives, Inc. v. Prince Mfg., Inc., 73 F.3d 1573, 1581 (Fed. Cir.1996) (rejecting district court's decision that remarks effected an estoppel because remarks were "equivocal," not "unmistakable"). Bard asserts that it did not "unmistakably" surrender its claims to an unpleated device, and so prosecution history...

To continue reading

Request your trial
3 cases
  • Masimo Corp. v. Philips Elecs. N. Am. Corp.
    • United States
    • U.S. District Court — District of Delaware
    • April 2, 2013
    ...v. Shoketsu Kinzoku Kogyo Kabushiki Co., Ltd., 344 F.3d 1359, 1368 (Fed. Cir. 2003) (en banc). 754. C.R. Bard, Inc. v. U.S. Surgical Corp., 107 F. Supp. 2d 489, 492 (D. Del. 2000) (citation omitted). 755. Id. at 494 (listing examples including "(i) amendments made to overcome patentability ......
  • C.R. Bard, Inc. v. U.S. Surgical Corp.
    • United States
    • U.S. Court of Appeals — Federal Circuit
    • October 29, 2004
    ...that U.S. Surgical did not infringe claim 20 literally or under the doctrine of equivalents. C.R. Bard, Inc. v. United States Surgical Corp., 107 F.Supp.2d 489, 491-94 (D.Del.2000) ("Summary judgment order"). The district court, however, denied U.S. Surgical's motion for summary judgment on......
  • Bayer Cropscience AG v. Dow Agrosciences LLC, Docket No. 18
    • United States
    • U.S. District Court — District of Delaware
    • December 30, 2011
    ..."as a limit on the scope of patent available to a claimant under the [Doctrine of Equivalents]"); C.R. Bard, Inc. v. U.S. Surgical Corp., 107 F. Supp. 2d 489, 493 (D.Del. 2000)("Under prosecution history estoppel, the patentee is estopped from enforcing the patent against an equivalent [dev......

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT